Audentes Therapeutics Inc (NASDAQ:BOLD) VP Suyash Prasad sold 8,000 shares of Audentes Therapeutics stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $28.53, for a total value of $228,240.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Shares of Audentes Therapeutics Inc (BOLD) traded down $0.29 during mid-day trading on Wednesday, hitting $27.38. The company’s stock had a trading volume of 130,700 shares, compared to its average volume of 148,087. Audentes Therapeutics Inc has a one year low of $13.90 and a one year high of $33.43.

Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.88). equities research analysts predict that Audentes Therapeutics Inc will post -3.52 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new stake in shares of Audentes Therapeutics in the third quarter valued at approximately $143,000. Nationwide Fund Advisors boosted its stake in shares of Audentes Therapeutics by 288.9% in the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after buying an additional 6,384 shares in the last quarter. Trexquant Investment LP purchased a new stake in shares of Audentes Therapeutics in the third quarter valued at approximately $295,000. State of Wisconsin Investment Board purchased a new stake in shares of Audentes Therapeutics in the second quarter valued at approximately $210,000. Finally, Rhumbline Advisers purchased a new stake in shares of Audentes Therapeutics in the second quarter valued at approximately $252,000. Hedge funds and other institutional investors own 78.99% of the company’s stock.

Several research analysts have weighed in on BOLD shares. Zacks Investment Research downgraded Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Evercore ISI started coverage on Audentes Therapeutics in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 target price on the stock. ValuEngine downgraded Audentes Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, October 13th. BMO Capital Markets started coverage on Audentes Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $35.00 target price on the stock. Finally, William Blair started coverage on Audentes Therapeutics in a research note on Tuesday, October 17th. They issued an “outperform” rating and a $35.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. Audentes Therapeutics presently has an average rating of “Hold” and a consensus target price of $28.29.

ILLEGAL ACTIVITY NOTICE: “Audentes Therapeutics Inc (BOLD) VP Suyash Prasad Sells 8,000 Shares” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/06/audentes-therapeutics-inc-bold-vp-suyash-prasad-sells-8000-shares.html.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Insider Buying and Selling by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Stock Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related stocks with our FREE daily email newsletter.